This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alcon Stock Gains Following UNITY VCS' Approval in Canada
by Zacks Equity Research
ALC's UNITY VCS gets Canada's approval, advancing surgical precision with faster, more efficient technology.
Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks
by Zacks Equity Research
GKOS posts record Q1 on iDose TR strength, but reimbursement hurdles and legacy declines may hurt its near-term outlook.
Do Options Traders Know Something About Alcon Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to ALC stock based on the movements in the options market lately.
Is it Apt to Retain Alcon Stock in Your Portfolio for Now?
by Zacks Equity Research
ALC stays on investors' radar due to its Vision Care arm's performance and contributions from new products despite macro risks and stiff competition.
COO Q2 Earnings Signal Growth and Caution: How to Play the Stock?
by Zacks Equity Research
Cooper Companies beats fiscal second-quarter estimates and raises guidance, but faces fertility headwinds and inventory pressures. Is COO still a long-term growth play?
Alcon Stock Rises Following the FDA Approval of TRYPTYR
by Zacks Equity Research
FDA approves ALC's TRYPTYR, a new dry eye treatment with rapid tear production. The approval is supported by strong Phase 3 trial results.
Company News for May 15, 2025
by Zacks Equity Research
Companies in The News Are: ARCO,DT,EXEL,ALC
Alcon Q1 Earnings Miss Estimates, Stock Down, 2025 EPS View Lowered
by Zacks Equity Research
ALC ends the first quarter of 2025 on a disappointing note.
Alcon (ALC) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Alcon (ALC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Top Research Reports for Texas Instruments, Boeing & NextEra Energy
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments Incorporated (TXN), The Boeing Company (BA) and NextEra Energy, Inc. (NEE).
Ahead of Alcon (ALC) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Alcon (ALC) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Do Options Traders Know Something About Alcon Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to ALC stock based on the movements in the options market lately.
ALC Stock May Rise With the Introduction of PanOptix Pro in US
by Zacks Equity Research
Alcon introduces Clareon PanOptix Pro IOL to select practices across the United States, with commercial availability expected in May.
The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals
by Zacks Equity Research
Alcon, Glaukos and Regeneron Pharmaceuticals are part of the Zacks top Analyst Blog.
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space
by Urmimala Biswas
ALC, GKOS and REGN are well-positioned to benefit from the evolving space of cell-based ophthalmic therapy.
Avanos Medical (AVNS) Down 5.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alcon (ALC) Soars 6.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Alcon (ALC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Alcon Stock Might Rise as Clareon Vivity IOL Secures CE Mark Approval
by Zacks Equity Research
ALC secures CE Mark for Clareon Vivity IOL, bringing advanced presbyopia-correcting lens technology to Europe, enhancing visual outcomes with cutting-edge innovation.
ALC Stock Rises Following the Merger Agreement With LENSAR
by Zacks Equity Research
Alcon enters into a definitive merger agreement to acquire LENSAR's ALLY Robotic Cataract Laser Treatment System, proprietary Streamline software technology and LENSAR legacy laser system.
Is it the Right Time to Hold Alcon Stock in Your Portfolio Now?
by Zacks Equity Research
ALC stays on investors' radar due to its Surgical arm performance and contributions from new products.
Alcon Stock Gains From Innovation Despite Macroeconomic Troubles
by Zacks Equity Research
Within Vision Care, ALC is registering solid growth, banking on strong sales of its contact lenses and ocular health products.
Alcon Q4 Earnings Beat, Margins Rise, Stock Remains Stable in Afterhours
by Zacks Equity Research
ALC's performance is driven by robust demand for its innovative products, balanced geographic footprint and strong execution by the team.
Alcon (ALC) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Alcon (ALC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Wall Street's Insights Into Key Metrics Ahead of Alcon (ALC) Q4 Earnings
by Zacks Equity Research
Evaluate the expected performance of Alcon (ALC) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Avanos Medical (AVNS) Soars 7.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Avanos Medical (AVNS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.